Universal protection against influenza viruses by multi-subtype neuraminidase and M2 ectodomain virus-like particle | PLOS Pathogens
![Asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017–18 (PHIRST): a population cohort study - The Lancet Global Health Asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017–18 (PHIRST): a population cohort study - The Lancet Global Health](https://www.thelancet.com/cms/attachment/d04c0101-0b77-415e-bac3-53b8ae811a0f/gr1_lrg.jpg)
Asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017–18 (PHIRST): a population cohort study - The Lancet Global Health
![Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective - ScienceDirect Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1074761320303721-fx1.jpg)
Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective - ScienceDirect
![Figures and data in Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events | eLife Figures and data in Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events | eLife](https://iiif.elifesciences.org/lax/63537%2Felife-63537-fig1-figsupp4-v3.tif/full/1500,/0/default.jpg)
Figures and data in Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events | eLife
![Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses | Nature Communications Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-32149-8/MediaObjects/41467_2022_32149_Fig1_HTML.png)
Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses | Nature Communications
![Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract | Nature Reviews Microbiology Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract | Nature Reviews Microbiology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41579-021-00542-7/MediaObjects/41579_2021_542_Fig1_HTML.png)
Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract | Nature Reviews Microbiology
![Frontiers | Characterization of Influenza A and B Viruses Circulating in Southern China During the 2017–2018 Season Frontiers | Characterization of Influenza A and B Viruses Circulating in Southern China During the 2017–2018 Season](https://www.frontiersin.org/files/Articles/519986/fmicb-11-01079-HTML/image_m/fmicb-11-01079-g001.jpg)
Frontiers | Characterization of Influenza A and B Viruses Circulating in Southern China During the 2017–2018 Season
Relationship between hemagglutinin stability and influenza virus persistence after exposure to low pH or supraphysiological heating | PLOS Pathogens
Management and control of communicable diseases in schools and other child care settings: systematic review on the incubation pe
![Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial - The Lancet Infectious Diseases Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/7c0d7ba9-81c6-42c8-af68-6d61627d61f5/gr1_lrg.jpg)
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial - The Lancet Infectious Diseases
![A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge | PNAS A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge | PNAS](https://www.pnas.org/cms/10.1073/pnas.2025759118/asset/a4daa9c9-7cb0-4436-9215-f3e533c6a51e/assets/images/large/pnas.2025759118fig02.jpg)
A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge | PNAS
![Influenza ¦¦ Respiratory Screening ¦¦ Infection, Prevention & Control ¦¦ Applications ¦¦ Oxford Biosystems Influenza ¦¦ Respiratory Screening ¦¦ Infection, Prevention & Control ¦¦ Applications ¦¦ Oxford Biosystems](https://www.oxfordbiosystems.com/portals/0/images/Influena_virus.jpg)